Investigating the Potential Use of Chemical Biopsy Devices to Characterize Brain Tumor Lipidomes

Int J Mol Sci. 2022 Mar 24;23(7):3518. doi: 10.3390/ijms23073518.

Abstract

The development of a fast and accurate intraoperative method that enables the differentiation and stratification of cancerous lesions is still a challenging problem in laboratory medicine. Therefore, it is important to find and optimize a simple and effective analytical method of enabling the selection of distinctive metabolites. This study aims to assess the usefulness of solid-phase microextraction (SPME) probes as a sampling method for the lipidomic analysis of brain tumors. To this end, SPME was applied to sample brain tumors immediately after excision, followed by lipidomic analysis via liquid chromatography-high resolution mass spectrometry (LC-HRMS). The results showed that long fibers were a good option for extracting analytes from an entire lesion to obtain an average lipidomic profile. Moreover, significant differences between tumors of different histological origin were observed. In-depth investigation of the glioma samples revealed that malignancy grade and isocitrate dehydrogenase (IDH) mutation status impact the lipidomic composition of the tumor, whereas 1p/19q co-deletion did not appear to alter the lipid profile. This first on-site lipidomic analysis of intact tumors proved that chemical biopsy with SPME is a promising tool for the simple and fast extraction of lipid markers in neurooncology.

Keywords: SPME; brain tumor; chemical biopsy; glioma; heterogeneity; lipids.

MeSH terms

  • Biopsy
  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / pathology
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Lipidomics*
  • Lipids
  • Mutation

Substances

  • Lipids
  • Isocitrate Dehydrogenase